Peptide Modulation Overrides Glycan Synergy in Gold Nanoparticle-Based Vaccines for Cancer Immunotherapy

Area of Science:

• Nanotechnology
• Immunology
• Oncology

Background:

• Previously developed gold nanoparticle (GNP)-based integrated glyco-nanovaccines (iGN) for anti-cancer immunotherapy.
• iGN combines GNPs with a toll-like receptor (TLR) 7 ligand, antigen peptide, and sugar chain (mannose).
• The role of different sugar chains and antigen peptides in iGN efficacy requires further investigation.

Purpose of the Study:

• To compare the anti-tumor effects of two different sugar chains: α-mannose and sialic acid in iGN.
• To elucidate the impact of antigen peptides on iGN cellular uptake and immunotherapeutic function.

Main Methods:

• Synthesis and characterization of iGN with α-mannose or sialic acid modifications.
• Evaluation of nanoparticle uptake by bone marrow-derived dendritic cells (BMDCs).
• Assessment of TLR 7 ligand delivery and immune cell activation (type I interferon pathway).
• In vivo anti-tumor efficacy studies in a mouse tumor model (EG7 syngeneic model).

Main Results:

• Sugar chain type influences iGN uptake; α-mannose promotes, while sialic acid limits BMDC internalization.
• Antigen peptide integration, particularly ovalbumin peptides, significantly enhances iGN uptake and TLR 7 ligand delivery.
• Sialic acid-modified iGN with peptides showed comparable CD8+ T cell induction and anti-cancer efficacy to α-mannose-modified iGN.

Conclusions:

• Antigen peptides critically determine iGN cellular internalization and immunotherapeutic efficacy, overriding sugar chain effects.
• This study establishes a new design principle for glyco-nanovaccines, emphasizing peptide-driven therapeutic outcomes.
• Peptide modification offers a strategy to enhance the efficacy of nanoparticle-based cancer immunotherapies.